Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tactical Therapeutics

Tactical Therapeutics?uq=UG6efJS6
2005 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE (Cancelled)
Description

Provider of a Biopharmaceutical anti-cancer compound for solid tumors and primary brain cancers. The lead drug, carboxyamidotriazole orotate (CTO) (Pravitinib), inhibits multiple tyrosine kinases through modulating calcium signaling pathways. The company is seeking funding, partnering or out-licensing to ensure randomized Phase II trials of CTO are conducted to develop CTO for the treatment of malignant gliomas and glioblastoma.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 44 Wall Street
  • Suite 2003
  • New York, NY 10005
  • United States

+1 (212) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tactical Therapeutics’s full profile, request a free trial.

Tactical Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 12-Oct-2016 Cancelled Clinical Trials - Phase 1
1. Angel (individual) Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Tactical Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Rashida Karmali Ph.D Founder & Chief Executive Officer